|Dr. Stelios Papadopoulos||Co-Founder & Chairman||N/A||N/A||69|
|Dr. Michael M. Morrissey Ph.D.||CEO, Pres & Director||1.65M||1.2M||56|
|Mr. Christopher J. Senner||Exec. VP, CFO & Principal Accounting Officer||844.62k||N/A||49|
|Dr. Peter Lamb Ph.D.||Exec. VP of Scientific Strategy & Chief Scientific Officer||720.25k||1.35M||56|
|Mr. Jeffrey J. Hessekiel J.D.||Exec. VP, Gen. Counsel & Sec.||760k||956k||48|
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Exelixis, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 6.